Dicot Strenghten"s Team with new Supply Chain Director
Press release: Uppsala, October 4, 2019. Dicot AB (publ, developer of drugs targeting sexual dysfunction, today announced that the company has contracted Catarina Malmberg as its Supply Chain Director, effective of November 1, 2019. In this role Malmberg will be responsible for both supply of raw material and production through the entire supply chain.
Press release: Uppsala, October 4, 2019. Dicot AB (publ, developer of drugs targeting sexual dysfunction, today announced that the company has contracted Catarina Malmberg as its Supply Chain Director, effective of November 1, 2019. In this role Malmberg will be responsible for both supply of raw material and production through the entire supply chain.
For further information, please contact:
Julie Silber, CFO and Director of Investor Relations, Dicot / Gabriela Urquilla, Director of Communications & Vice President of Investor Relations
Tel: +46 (0)79 348 62 77 / +46 (0)72-396 72 19
E-mail: [email protected] / [email protected]
About Dicot AB
Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients" lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company"s lead product, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. For more information see www.dicot.se.
Filer
Om Dicot
Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.
Handelsinformation
IR-Kontakt
